Solasia Pharma K.K.
JPX: 4597.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yoshihiro Arai
- Employees
- 23
- Headquarters
- Tokyo, Japan
- IPO year
- 2017
- Market cap
- ¥8.7B
- Website
- https://www.solasia.co.jp
Loading 4597…
Loading profile data…Frequently asked questions about 4597
What does Solasia Pharma K.K. (4597.T) do?
Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery syste...
Where does 4597.T trade?
Solasia Pharma K.K. (4597.T) trades on the Tokyo Stock Exchange.
What sector is 4597.T in?
Solasia Pharma K.K. (4597.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Solasia Pharma K.K.?
Yoshihiro Arai is the chief executive officer of Solasia Pharma K.K. (4597.T).
Where is Solasia Pharma K.K. headquartered?
Solasia Pharma K.K. is headquartered in Japan.
Does 4597.T pay a dividend?
Solasia Pharma K.K. (4597.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4597.T go public?
Solasia Pharma K.K. (4597.T) completed its initial public offering in 2017.